Aspire Biopharma Holdings, Inc. · NASDAQ:ASBP
Aspire Biopharma — Investor Presentation (November 2025)
24 slides from Aspire Biopharma's investor presentation, November 2025
Slide 1: Investor Presentation
November 2025 Investor Presentation Nasdaq: ASBP
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by t
Slide 3: Aspire at a Glance
Aspire at a Glance Patent-pending drug delivery technology for rapid sublingual absorption and entry into the bloodstream of drugs and supplements ▪ Enhances the pharmacokinetic performance of Active Pharmaceutical Ingredients (“APIs”), supplements and nutraceuticals into the bloodstream, increasing
Slide 4: Drug and Supplement Delivery Technology Innovator
Drug and Supplement Delivery Technology Innovator Aspire Biopharma has developed Technology delivers fast acting New mechanism of delivery disruptive technologies for drug formulations using our allows rapid sublingual delivering drugs and other absorption into the products sublingually(1). patent-p
Slide 5: Drug and Supplement Delivery Technology Innovator
Drug and Supplement Delivery Technology Innovator Fast Acting Powder-form medication developed using our patent-pending technology enters the bloodstream in a fraction of the time as compared to oral tablets and capsules Easy to Use Dissolves easily under the tongue Dosage Management Drugs do not fi
Slide 6: Aspire’s Mechanisms of Action
Aspire’s Mechanisms of Action Mouth to Blood Stream Pathways Nature Provides the Mouth with Direct Access to Blood Stream Dorsalis Lingual Artery Lingual Vein Aspire’s sublingual delivery system avoids the Veins of Dorsum of Tongue side effect drugs delivered in pills or tables orally ▪ Avoid damage
Slide 7: Overview – The Technology
Overview – The Technology 7
Slide 8: Aspire Pipeline, Commercial Opportunities & Planned 2025 Milestones
Aspire Pipeline, Commercial Opportunities & Planned 2025 Milestones Aspirin Products Non-Aspirin Prescription Drug Products ▪ Alprazolam formulation for sublingually administration (generic form High Dose of Xanax); Phase 1 clinical test planned for 2026. ✓ Completed clinical trial to evaluate the p
Slide 9: Market Opportunity
Market Opportunity Aspire believes its disruptive technology can be applied to a number of approved drugs and supplements Global Analgesics Market Valued at $47.32B in 2023 and projected to reach $75.73B by 2032, growing at a compound annual growth rate (CAGR) of 5.39% over the forecast period 2024-
Slide 10: Sublingual Aspirin Product: Background
Sublingual Aspirin Product: Background Oral aspirin (ASA) with its anti-inflammatory properties has been used world-wide for over 100 years Aspirin is one of the most-studied and understood drugs and universally approved for use. In the past Aspirin-induced GI bleeding has limited the long-term oral
Slide 11: Sublingual Aspirin Product: Clinical Trial
Sublingual Aspirin Product: Clinical Trial Strategy Aspire uses existing, approved generic-drug dosages. Generic drugs do not need to repeat the clinical trials related to active ingredients but must demonstrate sublingual route of administration as it pertains to: • effectiveness • amount of drug t
Slide 12: Sublingual Aspirin Product: Overview and Top-Line Clinical Results
Sublingual Aspirin Product: Overview and Top-Line Clinical Results Study Design and Top-Line Results Plasma ASA Concentrations (ng/mL) over 30 Minutes after ▪ Primary objective of the clinical trial was to evaluate the bioavailability Dosing of acetylsalicylic acid (ASA, the active antiplatelet form
Slide 13: Sublingual Aspirin Product: Overview and Top-Line Clinical Results
Sublingual Aspirin Product: Overview and Top-Line Clinical Results Mean Serum TxB2* Concentrations (ng/mL) (lower concentrations mean less platelet aggregation) over 30 Minutes after Dosing OTASA BA2038 (Aspire Additional Important Clinical Trial Findings sublingual aspirin granules), OTASA BA002039
Slide 14: Sublingual Aspirin Product Commercialization and Go-to-Market Strategy
Sublingual Aspirin Product Commercialization and Go-to-Market Strategy Launch product initially in the Rx market, likely through licensing or partnering agreements Partner with an experienced end-to-end marketing and distribution firms Significant potential licensing opportunities with leading drug
Slide 15: Manufacturing Strategy
Manufacturing Strategy A contract manufacturing strategy is being pursued with the potential for multiple supplier relationships to reduce risk and capex investments Glatt Air Techniques ▪ Technical Manufacturing Development Partner ▪ Produced low-dose aspirin product and performed studies in 2023 ▪
Slide 16: Sublingual Aspirin Product: Analgesics Market Opportunity
Sublingual Aspirin Product: Analgesics Market Opportunity Non-opioid analgesic and opioid markets combined currently estimated at $80+B and projected to grow to nearly $100B in five years 2022 2023 2024 2025 2026 2027 Market Data ($-Bil) Opioids $32.5 $33.6 $34.6 $35.7 $36.8 $37.9 Analgesics $48.0 $
Slide 17: BUZZ BOMB New Sublingual Caffeine Supplement
BUZZ BOMB New Sublingual Caffeine Supplement Single serving 50mg caffeine supplement utilizing Aspire's patent-pending and proprietary sublingual delivery technology • Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the caffeine ma
Slide 18: BUZZ BOMB New Sublingual Caffeine Supplement
BUZZ BOMB New Sublingual Caffeine Supplement BUZZ BOMB Caffeine Supplement Launched at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World, in August 2025 • 30,000 BUZZ BOMB sample packs of four 50mg stick packs in each flavor distributed to convention attendees • Well-known fitn
Slide 19: BUZZ BOMB Disruptive Characteristics
BUZZ BOMB Disruptive Characteristics BUZZ BOMB Caffeine Supplement Benefits: • Speed - works nearly immediately (less than 2 minutes) vs. 20-30 minutes • Convenience – small, easy to use single-use packets (no mixing and measuring for beverages) • Energy management - use as needed to precisely manag
Slide 20: BUZZ BOMB Buzz at the Fitness Conventions
BUZZ BOMB Buzz at the Fitness Conventions BUZZ BOMB Testimonials from Leading Figures in the Fitness World Bobby Maximus is a UFC fighter, Ju Jitsu Masters World Champion and fitness trainer who has broken multiple power-endurance world records and is recognized as a leading figure in the fitness wo
Slide 21: BUZZ BOMB Buzz at the Fitness Conventions
BUZZ BOMB Buzz at the Fitness Conventions 21
Slide 22: Pre-Workout Supplement Market
Pre-Workout Supplement Market • Global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030 ❖ Rising fitness culture and gym memberships ❖ Consumer focus on performance and recovery ❖ Expanding demographics (women, Gen Z, casua
Slide 23: Aspire’s Investment Considerations
Aspire’s Investment Considerations ▪ Multiple ℞ applications in heart attack/stroke, pain management, weight loss, testosterone, and others ▪ Large Addressable ℞ Markets: $80B combined analgesics and opioid market ▪ High Dose Aspirin Prescription Product: Trial demonstrated dramatically higher and m
Slide 24: Thank You.
Aspire BioPharma Holdings, Inc. Thank You. 23150 Fashion Drive, Suite 232 Estero, FL 33928 www.aspirebiolabs.com info@aspire-biopharma.com Investor Relations Kevin McGrath PCG Advisory kevin@pcgadvisory.com Nasdaq: ASBP 24
Aspire Biopharma Holdings — Investor Presentation (November 2025) on 6ix